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G EN E RA L ART I C L E
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Abstract
Identifying dosage-sensitive genes is a key to understand the mechanisms underlying intellectual disability in Down
syndrome (DS). The Dp(17Abcg1-Cbs)1Yah DS mouse model (Dp1Yah) shows cognitive phenotypes that need to be
investigated to identify the main genetic driver. Here, we report that three copies of the cystathionine-beta-synthase gene
(Cbs) in the Dp1Yah mice are necessary to observe a deficit in the novel object recognition (NOR) paradigm. Moreover, the
overexpression of Cbs alone is sufficient to induce deficits in the NOR test. Accordingly, overexpressing human CBS
specifically in Camk2a-expressing neurons leads to impaired objects discrimination. Altogether, this shows that Cbs
overdosage is involved in DS learning and memory phenotypes. To go further, we identified compounds that interfere with
the phenotypical consequence of CBS overdosage in yeast. Pharmacological intervention in Tg(CBS) mice with one selected
compound restored memory in the NOR test. In addition, using a genetic approach, we demonstrated an epistatic
interaction between Cbs and Dyrk1a, another human chromosome 21-located gene (which encodes the dual-specificity
tyrosine phosphorylation-regulated kinase 1a) and an already known target for DS therapeutic intervention. Further
analysis using proteomic approaches highlighted several molecular pathways, including synaptic transmission,
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cell projection morphogenesis and actin cytoskeleton, that are affected by DYRK1A and CBS overexpression. Overall, we
demonstrated that CBS overdosage underpins the DS-related recognition memory deficit and that both CBS and DYRK1A
interact to control accurate memory processes in DS. In addition, our study establishes CBS as an intervention point for
treating intellectual deficiencies linked to DS.
Significant statement
Here, we investigated a region homologous to Hsa21 and located
on mouse chromosome 17. We demonstrated, using three
independent genetic approaches, that the overdosage of the
cystathionine-beta-synthase gene (Cbs) gene encoded in the
segment is necessary and sufficient to induce a deficit in the
novel object recognition (NOR) test.
In addition, we identified compounds that interfere with the
phenotypical consequence of CBS overdosage in yeast and in
mouse transgenic lines. Then we analysed the relation between
CBS overdosage and the consequence of DYRK1a overexpression,
a driver of Down syndrome (DS) cognitive phenotypes found in
another region homologous to Hsa21. We demonstrated that an
epistatic interaction exists between Cbs and Dyrk1a and that it
affects different pathways, including synaptic transmission, cell
projection morphogenesis and actin cytoskeleton.
Introduction
Down Syndrome (DS) is the most common aneuploidy observed
in human. The presence of an extra copy of the human
chromosome 21 (Hsa21, Hsa for Homo sapiens) is associated
with intellectual disabilities and several specific morphological
and physiological features. Phenotypic mapping in human
bearing partial duplication highlighted the contribution of
several regions of the Hsa21 to DS features (1,2). Additional
information was collected from trisomic and monosomic
mouse models to detect genomic regions sensitive to dosage
and able to induce impairments in behaviour and other DS-
related traits (3–11). Most of the efforts focused on the region
homologous to the Hsa21 located on mouse chromosome 16
(Mmu16,Mmu for Mus musculus), highlighting the contribution of
overdosage of the amyloid precursor protein (12), the glutamate
receptor, ionotropic, kainate 1 (Grik1) or the dual-specificity
tyrosine phosphorylation-regulated kinase 1a (Dyrk1a) (13,14)
to DS cognitive defects. DYRK1A is currently the main target
for therapeutic intervention with the identification of a few
compounds inhibiting its kinase activity and improving mainly
cognition in DS mouse models (15–20). However, models
carrying trisomy of the region of Mmu17 homologous to the
Hsa21 also showed learning and memory defects (21,22) and
appeared to have a major impact on DS phenotypes in mouse
models (23). The Dp(17Abcg1-Cbs)1Yah (called here Dp1Yah)
mice are trisomic for 12 protein-encoding genes including
three members of the trefoil factor families (Tff1-3), Tmprss3,
Ubash3a,Rsph1, Slc37a1, Pknox1, Pde9a, Ndufv3,Wdr4 and Cbs. The
region also encompasses six non-coding genes: Gm25447 (rRNA),
Gm15318 (antisense lncRNA), Gm8437 (unclassified), Gm9902
(unclassified), 4833413E03Rik (lincRNA) and Gm24970 (miRNA).
The Dp1Yah mice are defective in the novel object recognition
(NOR) test and show long-lasting in vivo long-term potentiation
(LTP) in the hippocampus while the corresponding monosomy
in Ms2Yah mice (in which Abcg1 and U2af1 are deleted), induces
defects in social discrimination with increased in vivo LTP (24).
Interestingly, as observed in the rotarod test, the locomotor
phenotype of the Tc1 transchromosomic mouse model carrying
an almost complete Hsa21 is rescued when the Abcg1-Cbs region
is returned to two copies in Tc1/Ms2Yah mice (25). Similarly, the
trisomy of a larger overlapping segment on Mmu17 from Abcg1
to Rrp1b induces an increased LTP as compared with controls in
the Dp(17)Yey model (22) and was shown to genetically interact
with the trisomy of the Lipi-Zbtb21 interval. More specifically,
the trisomy of both the Abcg1-Rrp1b region and the Cbr1-Fam3b
region was detrimental for learning and memory in the Morris
water maze and for LTP in DS mouse models (23).
Among the 11 trisomic genes in the Dp1Yah model, the Cbs,
encodes a pyridoxal phosphate-dependent enzyme converting
homocysteine to cystathionine. This first step of the transsul-
furation pathway removes homocysteine from the methionine
cycle thereby also affecting the folate and the methylation path-
ways,while contributing to the cysteine cycle.Of note, in human,
homozygous loss-of-function mutations in CBS are associated
with homocystinuria (OMIN236200), a metabolic condition with
intellectual disability. CBS is also the major enzyme catalysing
the production of H2S from L-cysteine (26) or from the conden-
sation of homocysteinewith cysteine (27). H2S is now considered
a major gasotransmitter in the brain (28) and interferes with
synaptic transmission. Considering the up-regulated expression
of CBS in several brain regions of the Dp1Yah model and its
impact on intellectual disability, we decided to focus on Cbs and
decipher the role of CBS in DS cognitive phenotypes. To this
end, we generated and characterized constitutive and condi-
tional changes in Cbs dosage in the nervous system of various
mousemodels. In addition,we identified pharmacological drugs
able to counteract the phenotypical consequence of CBS over-
expression, in particular behavioural impairments, and finally
further analysed molecular changes induced by Cbs overdosage
to understand the mechanisms perturbed in DS models.
Materials and Methods
Ethics statement, mouse lines and genotyping
Animal experimentswere approved by theCom’EthN◦17 (project
file: 2012-069) and accredited by the FrenchMinistry for Superior
Education and Research and in accordance with the Directive of
the European Parliament: 2010/63/EU, revising/replacing Direc-
tive 86/609/EEC and with French Law (Decree n◦ 2013-118 01 and
its supporting annexes entered into legislation 01 February 2013)
relative with the protection of animals used in scientific experi-
mentation. YH was granted the accreditation 67-369 to perform
the reported experiments in the animal facility (Agreement C67-
218-40). For all these tests, mice were kept in specific pathogen-
free conditionswith free access to food andwater. The light cycle
was controlled as 12 h light and 12 h dark (lights on at 7 AM).
All the behavioural tests were performed between 9:00 AM and
4:00 PM.
Several mouse lines were used to decipher the influence of
Cbs dosage changes: the trisomic mouse model, Dp(17Abcg1-
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Cbs)1Yah, named here Dp1Yah, carries a segmental duplication
of the Abcg1-Cbs region of the Mmu17 (21) kept on the
C57BL/6 J genetic background with continuous backcross
during all the study (N > 7 generations); the inactivated
allele of C57BL/6 J.Cbstm1Unc (29); and the PAC transgenic line
Tg(CBS)11181Eri [named here Tg(CBS)], originally identified as
60.4P102D1 (30) and backcrossed on C57BL/6J for more than
seven generations. We designed, generated and selected the
transgenic mouse line Tg(Prp-gfp-CBS)95-157ICS, named here
Tg(Prp-gfp-CBS), to overexpress the human CBS cDNA from the
murine prion promoter region (containing a 8477 bp region
upstream of the ATG of the murine prion gene, i.e. 6170 bp
promoter region, exon 1, intron 1 and beginning of exon 2) after
the excision of a loxP-gfp-loxP interrupting cassette (Fig. 3A).
The transgenic mouse line was generated on the C57BL/6N
genetic background. We used the transgenic Tg(Camk2a-
cre)4Gsc mouse line (31), named here Tg(Camk2a-cre), as a
glutamatergic neuron-specific Cre driver. The line was further
bred on C57BL/6J for more than seven generations. When
the Tg(Camk2-Cre)/0 × Tg(Prp-gfp-CBS)/0 cross was done,
the genetic background of the cohorts was estimated to be
around C57BL6 J(57%)/N(43%). The Dyrk1a BAC transgenicmouse
line, named here Tg(Dyrk1a), was previously generated in our
laboratory (32,33) and their study was performed on animals
with more than seven generations of backcross on the C57BL/6J
genetic background. The cohorts for the Tg(Dyrk1a) and Dp1Yah
were produced on the B6J genetic background (estimated at
98.8%). Genotype identification was performed on genomic DNA
isolated from tail biopsies with specific PCR (Supplementary
Material, Table S1).
Behavioural analysis
The number of animals required for behavioural analysis was
estimated according to similar experiments we previously per-
formed in DS mouse models (5,21,25). All the mice used in
the study were males and the controls were littermates. To
investigate the role of Cbs in the Dp1Yah cognitive phenotypes,
we generated two independent cohorts [cohort 1 (C1): wild-
type (wt) littermates n = 11; Cbstm1Unc/+, n = 8; Dp1Yah, n = 8;
Dp1Yah/Cbstm1Unc, n = 11; and cohort 2 (C2): wt littermates n = 18;
Cbstm1Unc/+, n = 15; Dp1Yah, n = 15; Dp1Yah/Cbstm1Unc, n = 10].
All cohorts were evaluated in several tests in adult mice, the
open field (C1: 33 weeks, C2: 14–16 weeks), NOR (C1: 33 weeks,
C2:14–16 weeks), Y-maze (C2: 15–19 weeks) and rotarod (C2: 25–
28 weeks of age).
Wt littermates (n = 13) and Tg(CBS)/0 (n = 17) hemizy-
gotes were tested for circadian actimetry (14 weeks), Y-Maze
(16 weeks), open field (17 weeks) and NOR (17 weeks). We added
an additional group of wt (n = 9) and Tg(CBS)/0 (n = 10) to
validate the results obtained in the NOR test for which animals
were tested at the same age (17 weeks). A cohort with four
genotypes [wt (n = 13), Tg(Camk2-Cre)/0 (n = 11), Tg(Prp-gfp-
CBS)/0 (n = 12) and Tg(Camk2-Cre)/0, Tg(Prp-gfp-CBS)/0 (n = 14)]
was evaluated through the same behavioural tests: rotarod
(14 weeks), Y-maze (16 weeks), open field (19–20 weeks) and
NOR (19–20 weeks). A total of 14 wt, 15 Tg(Dyrk1a), 13 Dp1Yah
and 13 Dp1Yah/Tg(Dyrk1a) mutant mice were evaluated for the
open field exploration (11–12 weeks), NOR test (11–12 weeks)
and Y-maze (13 weeks). A second independent cohort with 11
wt, 10 Tg(Dyrk1a), 14 Dp1Yah and 10 Dp1Yah/Tg(Dyrk1a) was
used for the Morris water maze learning test (14–16 weeks).
The behavioural protocols for open-field, Y-maze and NOR,
rotarod, water maze were detailed in the Supplementary
information.
Drug screening in yeast
All plasmids were generated using standard procedures.
Restriction enzymes and Taq polymerase were obtained from
NewEngland Biolabs (Evry, France). T4DNA ligasewas purchased
from Promega and purified synthetic oligonucleotides from
Eurogentec. Routine plasmid maintenance was carried out
in DH5α and TOP10 bacteria strains. Yeast cystathionine b-
synthase (Cys4) coding sequence was amplified from the
genomic DNA of the W303WT strain (see genotype below) using
Bam-Cys4-F: CGGGATCCCGATGACTAAATCTGAGCAGCAAG and
Xho-Cys4-R: GCCTCGAGTCTTATGCTAAGTAGCTCAGTAAATCC
(that introduced BamHI andXho1 restriction sites) and subcloned
in the high copy number 2 μ-derived vectors p424-GPD and
p426-GPD, each time under the control of the strong constitutive
GDP promoter (34). Transformation of yeast cells was performed
using a standard lithium acetate method (35).
The yeast strain used in this study is derived from the W303
wt strain: MATa, leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-
11,15. The media used for yeast growth were the following: YPD
[1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) glucose],
for untransformed cells and synthetic dextrose minimal medium
(SD medium) composed of 0.67% (w/v), yeast nitrogen base w/o
amino acids and complemented with 0.1% (w/v) casamino acid,
40 mg/l adenine and 2% (v/v) glucose for Cys4-transformed cells.
Solid media contained 2% (w/v) agar.
For the drug screening, yeast cells were grown in uracil-
and tryptophan-free minimal liquid medium (SD-Ura/Trp) in
overnight liquid cultures at 29◦C. The following day, cells were
diluted to OD600∼0.2 in fresh medium and grown for 4 h to
reach exponential phase. Then 350 μl of exponentially growing
yeast cells overexpressing Cys4, adjusted to an OD600 of 0.5, were
spread homogeneously with sterile glass beads (a mix of ∼1.5
and 3 mm diameter) on a square Petri dish (12 cm × 12 cm)
containing uracil-, tryptophan- and methionine-free minimal
agar-based solid medium (SD-Ura/Trp/Met) containing 2% (w/v)
serine. Sterile filters (Thermo Fisher similar to those used for
antibiograms) were placed on the agar surface, and 2 μl of an
individual compound from the various chemical libraries were
applied to each filter. In addition, for each Petri plate, DMSO, the
vehicle,was added as a negative control on the top left filter, and
2 nmol of methionine as a positive control on the bottom right
filter. Plates were then incubated at 33◦C for 3 days and scanned
using a Snap Scan1212 (Agfa).
Two repurposed drug libraries were screened: the Prestwick
Chemical Library® (1200 drugs) and the BIOMOL’s FDA approved
drug library (Enzo Life Sciences, 640 drugs). In addition, the
Prestwick Phytochemical library (691 green compounds, most of
them being in use in human) was also screened. The compounds
were supplied in 96-well plates as 10 mm (for the two Prestwick®
libraries) and 2 mg/ml (BIOLMOL®) DMSO solutions. Disulfiram
(DSF) was purchased from Sigma-Aldrich and resuspended in
DMSO.
Mouse model treatment with disulfiram
A pre-clinical protocol was designed to target cognitive defects
correlated to CBS overexpression in Tg(CBS) mice brain (Fig. 4D).
The selected molecule was DSF, a potent inhibitor of mitochon-
drial aldehyde dehydrogenase (ALDH) used for the treatment of
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chronic alcoholism. We based our experiment on the work of
Kim et al. (36) in which the DSF effect on ethanol sensitization
in mice was demonstrated.
Behavioural studies were conducted in 12–16 week-old ani-
mals; to do so, we generated three independent cohorts, in
which we tested four conditions taking into account the dose
of DSF (or vehicle alone) and the genotype. For the cohorts (C1–
C3), we produced respectively 5,7,3 (n = 15 in total) wt mice
treated with vehicle, 5,3,6 (n = 14 in total) transgenic mice for
human CBS [Tg(CBS)] treated with vehicle, 7,5,3 (n = 15 in total)
wt mice treated with 10 mg/kg/day of DSF, 6,6,8 (n = 20 in
total) Tg(CBS) mice treated with 10 mg/kg/day of DSF based on
the dose previously administrated in the reference publication
(37). The local ethics committee, Com’Eth (n◦17), approved the
mouse experimental procedures, under the accreditation num-
ber APAFIS#1564-2015083114276031 with YH as the principal
investigator in this study. All assessments were scored blind
to genotype and animals were randomly distributed to experi-
mental groups and treatment as recommended by the ARRIVE
guidelines (37,38). DSF was prepared at 10 mg/mL in DMSO,
aliquoted and stored below −20◦C. The final formulation was
prepared just prior to use as a 1 mg/mL solution diluted in
Cremophor EL Castor oil (BASF)/H2O ready for injection (15/75),
to reach a final DMSO/Cremophor/H2O 10/15/75 (v/v/v) mix.
Treated animals received a daily dose (10 days) of this formu-
lation by intraperitoneal injection of 10 mg/kg/day. Non-treated
animals received the same formulation without DSF. On day
10 of treatment, the animals were habituated 30 min into the
arena. On day 11, animals were tested in the NOR paradigm to
assess recognitionmemory after 1 h retention as described in the
open field and object recognition task protocols (Supplementary
information).
Quantitative proteomic analysis
We collected five hippocampi of littermates of the four geno-
types: wt, Dp1Yah, Tg(Dyrk1a)/0 and [Dp1Yah,Tg(Dyrk1a)/0] after
their behavioural evaluation at the age of 25–27 weeks. Samples
were reduced, alkylated and digested with LysC and trypsin at
37◦C overnight. Five sets of samples with one sample from each
genotype (four in total) were labelled with Thermo Scientific
Tandem Mass isobaric tag (TMT), pooled and then analysed
using an Ultimate 3000 nano-RSLC (Thermo Scientific, San Jose
California) coupled in linewith anOrbitrap ELITE (Thermo Scien-
tific, San Jose California). An additional set was done comparing
all the wt controls together. Briefly, peptides were separated
on a C18 nano-column with a linear gradient of acetonitrile
and analysed in a top 15 higher collision dissociation data-
dependentmass spectrometry. Data were processed by database
searching using SequestHT (Thermo Fisher Scientific) with Pro-
teome Discoverer 1.4 software (Thermo Fisher Scientific) against
a mouse Swissprot database. Precursor and fragment mass tol-
erance were set at 7 and 20 ppm, respectively. Trypsin was set as
an enzyme and up to two missed cleavages were allowed. Oxi-
dation (M) and TMT-labelled peptides in primary amino groups
(+229.163 Da K and N-ter) were set as variable modification
and carbamidomethylation (C) as a fixed modification. We then
compared our five wt samples to determine the sample closer
to average score from the group and defined it as the reference
sample. All the protein quantification was performed based on
the reference wt sample. In total, we detected 1655 proteins
filtered with false discovery rate at 5% with a minimum of two
peptides for a given protein detected per genotypes. We calcu-
lated the mean of the fold change for each protein from all the
samples [Dp1Yah, Tg(Dyrk1a) and Dp1Yah/Tg(Dyrk1a)] compared
to control. From the preliminary data, we selected 208 proteins
with variability levels below 40% and a fold change below 0.8 or
above 1.2.
Western blot analysis
Ten micrograms of total proteins from cortex extracts were
electrophoretically separated in SDS-polyacrylamide gels (10%)
and then transferred to nitrocellulose membrane (120 V) during
1 h 30min.Non-specific binding siteswere blockedwith 5% skim
milk powder in tween–tris-buffer saline (TTBS) 1 h at room tem-
perature. Immunoblotting was carried out with primary anti-
body (Supplementary Material, Table S3) incubated overnight at
4◦C. The next day, we started with three washing baths with
TTBS, followed by secondary conjugated with horseradish per-
oxidase. The immunoreactions were visualized by ECL chemilu-
minescence system (ClarityTM western ECL substrate, Bio-Rad);
epifluorescence was captured with AmershamTM Imager 600.
Bands were detected at 18, 25 and 75 kDa, respectively for alpha-
synuclein (SNCA), synaptosomal-associated protein 25 (SNAP25)
and fused in sarcoma (FUS) and signals were quantified with
ImageJ.
Results
Three copies of Cbs are necessary to induce cognitive
impairments in the Dp1Yah mice
To challenge the hypothesis that three copies of Cbs are
necessary to induce behavioural deficits in the Dp1Yah mice,
we combined the Dp1Yah mice with the Cbstm1Unc/+ knock-out
model (29) and we compared the Dp1Yah with Dp1Yah/Cbstm1Unc
(in which only two copies of Cbs are functional), wt and
Cbstm1Unc/+ heterozygote controls. In the open field test, all of
the genotypes displayed similar exploratory behaviour, except
for the Dp1Yah/Cbs mice that travelled more distance in the
open field arena with a higher speed (Fig. 1A left panel; one-
way ANOVA on distance, post hoc Tukey test: Dp1Yah versus
Dp1Yah/Cbs+/tm1Unc P = 0.002; Fig. 1A right panel, one-way ANOVA
on speed, post hoc Tukey test: wt versus Dp1Yah/Cbs+/tm1Unc
P = 0.004, Cbs+/tm1Unc versus Dp1Yah/Cbs+/tm1Unc P = 0.05,
Dp1Yah versus Dp1Yah/Cbs+/tm1Unc P = 0.007). We confirmed
the increased activity of the Dp1Yah/Cbstm1Unc in the Y-maze
revealed by a higher number of arm entries compared with
the other genotypes (Fig. 1B, Kruskal–Wallis one-way ANOVA
on ranks—genotypes, post hoc Dunn’s method: wt versus
Dp1Yah/Cbs+/tm1Unc P < 0.05, Dp1Yah versus Dp1Yah/Cbs+/tm1Unc
P < 0.05) but no impact on spontaneous alternation (SA) [one-
way ANOVA, F(3, 87) = 2.486 P = 0.066]. To determine if the
motor activity was altered in the Dp1Yah/Cbstm1Unc model, we
used the rotarod test. After the first day of training, we did
not find any change, for all tested genotypes, in the maximum
speed reached before falling [Fig. 1C, speed: repeated measures
ANOVA variable «genotype» and «day», F(3, 110) = 1.816 P = 0.155].
Nevertheless, we observed a decrease in the locomotor learning
of the Dp1Yah mice during the following days of training. This
locomotor learning deficit was rescued in the Dp1Yah/Cbstm1Unc
mutant [Fig. 1C, speed: repeated measures two-way ANOVA
variable «genotype» and «day», F(2, 165) = 17.171 P < 0.001 post
hoc Tukey method wt «day 1 versus day 3» P = 0.002, Cbstm1Unc/+
«day 1 versus day 3» P < 0.001, Dp1Yah «day 1 versus day 3»
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P = 0.238, Dp1Yah/Cbstm1Unc «day 1 versus day 3» P = 0.017].
During the test phase, we found that the Dp1Yah individuals
had a weaker performance compared with Cbstm1Unc/+ and
Dp1Yah/Cbstm1Unc [ANOVA, variable «speed» and «genotype»
F(3, 385) = 5.544 P < 0.001 post hoc Tukey method, «wt versus
Dp1Yah» P = 0.099, «Cbstm1Unc/+ versus Dp1Yah» P = 0.001,
«Dp1Yah versus Dp1Yah/Cbstm1Unc» P = 0.01].
Then we tested object memory. No difference was observed
during the exploration of the familiar object in the presenta-
tion phase of the test (Fig. 1D, top left panel). However, during
the discrimination phase, after 1 h of retention, the Dp1Yah
mutant mice were not able to differentiate the novel object
from the familiar one (Fo) whereas the wt, Cbstm1Unc/+ and the
Dp1Yah/Cbstm1Unc spent significantly more time exploring the
new object (No) than the Fo [Fig. 1D, left bottom panel; two
ways ANOVA, variables ‘genotype’ and ‘objects’: F(3, 56) = 2.86
with P = 0.045; post hoc Tukey method wt ‘fam versus new’
q = 4.885 and P = 0.001; Cbstm1Unc/+ q = 3.913 and P = 0.008;
Dp1Yah, q = 0.503 and P = 0.724; Dp1Yah/Cbstm1Unc/+ q = 4.715 and
P = 0.002]. Accordingly, the recognition index showed that the
restoration of two functional copies of Cbs in the Dp1Yah mice
rescuedmemory performance in object recognition (Fig. 1D right
panel, one sample t-test: wt P = 0.05, Cbstm1Unc/+ P = 0.01, Dp1Yah
P = 0.82; Dp1Yah/Cbstm1Unc/+ P = 0.05).
Overall this set of experiments demonstrated that three
copies of Cbs are necessary to induce the Dp1Yah phenotypes
in the NOR test. In addition, rescuing Cbs dosage induced a
slight hyperactive phenotype during the exploration of a new
environment and restored performance in the rotarod activity.
Interestingly, returning back to wt level of expression of Cbs in
the Abcg1-Cbs region enables another trisomic gene from this
region to impact on the locomotor activity during exploratory
behaviour of the mouse.
The sole overexpression of a human CBS transgene
impacts object recognition and locomotor activity
We used the Tg(CBS) model, a PAC transgenic line encompassing
a 60 kb fragment with the human CBS locus (30), to analyse
the impact of the sole increase of Cbs dosage on behaviour and
cognition. As shown in Figure 2A, no difference in the locomotor
activity was observed during the exploration of a new environ-
ment in the open field test between wt and transgenic litter-
mates [Student t-test distance: wt versus Tg(CBS)/0 P = 0.925,
speed wt versus Tg(CBS)/0 P = 0.925]. However, we found a higher
circadian activity for isolated individuals [Fig. 2C, Student t-test
wt versus Tg(CBS) P < 0.001] that results from an increased
locomotor activity during the habituation and the dark phase
(Fig. 2B). In the Y-maze (Figs 2D–E), no difference was detected
between Tg(CBS)/0 andwt controls for the number of arm entries
and the SA. In the NOR test, (Figs 2F–H) the Tg(CBS)/0 animals
spent more time sniffing the two identical objects during the
presentation phase than their control littermates [Fig. 2F, Stu-
dent t-test wt versus Tg(CBS)/0 P = 0.05] but were impaired
in object recognition as shown by their absence of discrim-
ination between novel and familiar objects [Fig. 2G, Student-
paired t-test wt ‘Fo versus No’ P = 0.008, Tg(CBS) ‘Fo versus
No’ P = 0.174] resulting in a recognition index (time on the
No/time on both objects) not significantly different from the 50%
chance level, [Fig. 2H: one sample t-test, significant difference
from 50%, wt P = 0.008, Tg(CBS)/0 P = 0.174]. Consequently, we
demonstrated that CBS overexpression is sufficient to induce
a deficit in the NOR memory and decreased locomotor activity
during the dark phase while having no effect during the light
phase.
Cbs overexpression in hippocampal and cortical
neurons induces behavioural defects similar to Dp1Yah
We then checked if we could induce the cognitive deficits
observed in DS mouse models by overexpressing Cbs in the
hippocampal and cortical neurons, brain parts involved in
learning and memory. Hence, we engineered the Tg(Prp-gfp-
CBS) mouse strain in which the human CBS cDNA can be
expressed from the prion promoter after the excision of the
gfp cassette flanked by loxP sites (Fig. 3A) and selected one
Tg(Prp-gfp-CBS) line with a pattern of expression in the anterior
part of the adult brain (Fig. 3B). We chose the Tg(Camk2a-cre)
(31), to direct the Cre expression in cortical and hippocampal
glutamatergic neurons and we verified the expression of the
human CBS in different brain regions of the double transgenic
[Tg(Prp-gfp-CBS)/0, Tg(Camk2a-cre)/0]. As expected, we found
expression levels comparable to the endogenous murine Cbs
gene in cerebellum while human CBS was overexpressed in the
hippocampus and the cortex (Fig. 3C). Littermate wt animals,
carrying the two single transgenic constructs and the two
transgenes were produced and tested for object recognition.
During the test, the control groups, namely wt, Tg(Prp-gfp-CBS)/0
and Tg(Camk2a-cre)/0, spent more time on the No than the Fo as
expected, while the double transgenic individuals were not able
to differentiate the No from the Fo as shown by the recognition
index or the percentage of exploration time {Fig. 3D; recognition
index, one sample t-test: wt P = 0.03; Tg(Camk2a-cre)/0 P = 0.03;
Tg(Prp-gfp-CBS)/0 P = 0.001; [Tg(Prp-gfp-CBS)/0; Tg(Camk2a-cre)/0]
P = 0.90; exploration time; twoways ANOVA, variables ‘genotype’
and ‘objects’: F(3, 76) = 8.59with P< 0.001; post hoc Tukeymethod
wt «No versus Fo» P < 0.001; Tg(Camk2a-cre)/0 «No versus Fo»
P = 0.001 and Tg(Prp-gfp-CBS)/0 «No versus Fo» P < 0.001; [Tg(Prp-
gfp-CBS)/0; Tg(Camk2a-cre)/0] «No versus Fo» P = 0.861}.
Measurements of the travelled distance in the open field and
number of visited arms in the Y-maze revealed hyperactivity
of the Tg(Camk2cre)/0 carrier groups [Figs 3E–F, openfield: one-
way ANOVA F(3, 49) = 4.80 P = 0.005, post hoc Holm–Sidak
«wt versus Tg(Camk2-Cre)/0» unadjusted P = 0.002, «Tg(Prp-
gfp-CBS)/0 versus Tg(Camk2-Cre)/0» P = 0.003); Y-maze: one-
way ANOVA F(3, 46) = 6.04 P = 0.001, post hoc Holm–Sidak
«wt versus Tg(Camk2-Cre)/0» P = 0.04, «Tg(Prp-gfp-CBS)/0 versus
Tg(Camk2-Cre)/0» P = 0.009, Tg(Prp-gfp-CBS)/0 versus Tg(Prp-gfp-
CBS)/0, Tg(Camk2a-cre)/0 P = 0.04). Similarly to the Dp1Yah and
Tg(CBS) animals, we did not find any alteration in the SA in
the Y-maze test [one-way ANOVA: F(3, 43) = 0.691 P = 0.563].
All the mice, whatever their genotype, performed equally well
during the training session of the rotarod (Fig. 3G) [training:
repeated measures ANOVA, variables «genotype» and «day», F(3,
90) = 2.011 P = 0.126; test: repeated measures ANOVA, variables
«genotype» and «day», F(2, 90) = 44.783 P< 0.001] aswell as during
the test session with increasing speed [repeated measures
ANOVA, variables «genotype» and «speed», F(18;322) = 0.631
P = 0.875]. Thus, as expected from the role of the cerebellum
in locomotor coordination, the overdose of CBS restricted to
cortical and hippocampal neurons did not interfere with the
locomotor activity.
Hence, overexpression of CBS is necessary and sufficient
to induce object memory defect in a 1 h retention test with
limited impact on other phenotypes. As such, CBS is a new gene
that overdosage alters cognition in DS mouse models and as a
consequence is likely to contribute to DS phenotypes.
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Figure 1. The Dp1Yah phenotypes are dependent on Cbs dosage. Dp1Yah trisomic mice (n = 23) were compared with Dp1Yah carrying a KO of Cbs (Dp1Yah/Cbstm1Unc,
n = 21), Cbstm1Unc/+(n = 23) and wt littermates (n = 29). Animals were analysed in two independent cohorts in the following tests: open field (A), Y-maze (B) and NOR
(D). The rotarod (C) test was assessed on one cohort with wt (n = 18) Cbstm1Unc/+ (n = 15), Dp1Yah (n = 15) and Dp1Yah/Cbstm1Unc (n = 10) littermates. (A) Distance
travelled and medium speed during the 30 min of the test were increased in the Dp1Yah/Cbstm1Unc compared with the wt genotype. (B) Increased exploration activity
was confirmed for the Dp1Yah/Cbstm1Unc mice compared with control littermates in the Y-maze while SA was not affected. (C) During the training session (left panel),
the Dp1Yah mice were not able to improve their performance on the rotarod by increasing the maximum of speed before they fall from the rod compared to the other
genotypes. Nevertheless, no change was observed between individuals with the four genotypes during the test phase (right panel). (D) The exploration time in the first
session of the NOR test (left upper panel) was not statistically different in the four genotypes but during the recognition phase, after 10min of retention, the recognition
index (right upper panel, time spent on the No/total time of exploration) was clearly lower in Dp1Yah mice as compared with the other genotypes and not statistically
different from chance (50%). Accordingly, the exploration time (left lower panel) spent by the Dp1Yah/Cbstm1Unc mice to explore the object showed that they were able
to differentiate the novel (No) versus familiar (Fo) object while the Dp1Yah were not. Data are represented as one point per individual tested and the mean of the group.
(Values represent means + S.E.M. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001).
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Figure 2. Transgenic mice overexpressing human CBS display DS-related
behaviour phenotypes.Wt (n = 13) and Tg(CBS)/0 littermates (n = 17), hemizygotes
for a human PAC containing the CBS gene, were tested for the open field (A),
circadian actimetry (B–C), Y-maze (D–E) and NOR (F, G and H). No phenotype
was found in the Tg during the exploration of a new environment in the
open field looking at the total distance travelled (left) and the speed (right).
However, increased activity was observed during home cage monitoring over
a light–dark–light cycle (B) with an increase in the distance travelled (C). In
the Y-maze (E), Tg(CBS)/0 animals displayed altered SA with no change in the
number of arm entries (D). In the NOR test (F), Tg(CBS)/0 mice displayed similar
exploration activity compared to wt littermates but they did not discriminate
the novel versus the familiar object when looking at the discrimination index
(G) and the percentage of exploration time for both objects (H). (Values represent
means + S.E.M. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001).
Identification of drugs that suppress the effects of
Cys4/CBS overexpression both in yeast and mouse
A few studies have reported the identification of CBS inhibitors
(39–44) but most of them were based on in vitro assays using a
recombinant CBS enzyme as a drug target and led to the isolation
of inhibitors with relatively low potency and limited selectivity,
hence leading to the idea that CBS may be an undruggable
enzyme. Therefore, we oriented toward an in cellulo phenotype-
based assay that would allow the identification of drugs that
interfere with the phenotypical consequences of CBS overex-
pression and thereby that do not necessarily directly target the
CBS enzyme.The budding yeast Saccharomyces cerevisiae contains
a functional homolog of CBS and has been shown to be a relevant
system to model pathophysiological mechanisms involved in
a number of human disorders and to perform chemobiological
approaches that aim at identifying both drugs and new thera-
peutic targets (45–51). We thus decided to create a yeast model
in which the phenotypical consequences of CBS overexpres-
sion may be easily and conveniently monitored in order to get
potential in cellulo high throughput drug screening procedure.
We reasoned that if we overexpressed CBS at a sufficient level,
this should lead to a decreased intracellular level of methionine,
similarly towhatwas shown in patients, and therefore that yeast
cells would become methionine auxotroph and thereby unable
to grow on methionine-free minimal media. As the human CBS
protein is not very stable in yeast cells and therefore cannot
be expressed at high levels (52), we decided to overexpress
Cys4p, the CBS homolog in S. cerevisiae. Cys4p presents the
same domains and domain organization as CBS apart from the
N-terminal heme-binding domain that is absent in the yeast
protein (53). To get a degree of methionine auxotrophy sufficient
to allow an efficient screening, we expressed Cys4 from the
strong constitutive GPD promoter from two different high copy
number 2 μ vectors (each present at ∼50 copies per cell) and
supplemented the growth medium with serine, which is one of
the Cys4p/CBS substrates that could otherwise become limiting
upon Cys4 overexpression (Fig. 4A).
Using this model, we tested ≈ 2200 compounds from three
different chemical libraries consisting mainly of repurposed
drugs for their ability to suppress the methionine auxotrophy
induced by Cys4p overexpression. We exploited a similar prin-
ciple as a yeast-based screening setup previously (46,47,49,54).
Briefly, we spread yeast cells overexpressing Cys4 on a solid
agar-based methionine-free minimal medium. Then we put
filters on the agar surface and add different drugs from chemical
libraries on each filter. After 3 days of incubation at 33◦C, active
compounds were identified by a halo of restored/enhanced
growth around the filter on which they were loaded (Fig. 4B).
The advantage of this method is that it allows in one simple
experiment numerous compounds to be tested across a large
range of concentrations due to the diffusion of the molecule
in the medium surrounding the filter onto which it was
deposited. This design drastically improves the sensitivity of the
screen because the screened compounds can be toxic at high
concentrations whereas being active at subtoxic concentrations.
We identified four different compounds, among which DSF
(Fig. 4C).
Next, we tested if DSF was able to restore the object recogni-
tion in themousemodel overexpressing human CBS. Three inde-
pendent cohorts of Tg(CBS) and control littermates were treated
with DSF (10 mg/kg/day) for 10 days before being tested for the
NOR. As shown in Figure 4D, DSF-treated transgenic animals
were restored in the NOR paradigmwhereas non-treatedmutant
animals were still not able to discriminate the No versus the
Fo. Interestingly, the wt-treated individuals were no more able
to perform the discrimination while the vehicle-treated controls
were able to do so [Student-paired t-test: vehicle-treated wt «No
versus Fo» P = 0.006, DSF-treated wt «No versus Fo» P = 0.11
and vehicle-treated Tg(CBS) «No versus Fo» P = 0.59, DSF-treated
Tg(CBS) «No versus Fo» P = 0.05].Altogether, these results confirm
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Figure 3. Selective overexpression of hCBS in glutamatergic neurons leads to impaired object recognition and altered locomotor activity. (A) A conditional transgene
Tg(Prp-gfp-CBS) was designed to overexpress the human CBS cDNA from themurine Prion promoter after the deletion of an interrupting GFP-coding cassette flanked by
loxP sites. (B) The GFP allowed to select one line that leads to expression in the anterior part of the brain. (C) When Cre is expressed from the Tg(Camk2-Cre) transgene,
the deletion can be monitored in regions of the brain of the animals (upper panel) using different pairs of primers while the overexpression of hCBSmRNA (labelled Hs)
is detected by qRT-PCR in different parts of the brain (Ce: Cerebellum, Co: Cortex, Hip: Hippocampus; lower panel) in the Tg(Camk2-Cre)/0, Tg(Prp-gfp-CBS)/0 animals
(orange bar). No change in the endogenousmurine CBS (Mm) is detected in Tg(Camk2-Cre)/0, Tg(Prp-gfp-CBS)/0 animals (orange bar) compared to wt animals (white bar).
(D) wt (n = 13), Tg(Camk2-Cre)/0 (n = 11), Tg(Prp-gfp-CBS)/0 (n = 12) and Tg(Camk2-Cre)/0, Tg(Prp-gfp-CBS)/0 (n = 14) littermates were evaluated for object discrimination
(D), in the open field (E), Y-maze (F) and rotarod (G). Mice overexpressing hCBS in glutamatergic neurons were unable to discriminate the novel versus the familiar object
as compared with the other control genotypes (D). Tg(Camk2-Cre)/0 mice displayed an enhanced locomotor activity in the open field but no change was detected in
the control, wt and Tg(Prp-gfp-CBS)/0, or in double transgenic animals (E). In the Y-maze, animals carrying the Tg(Prp-gfp-CBS)/0 or the activated form, Tg(Camk2-Cre)/0,
Tg(Prp-gfp-CBS)/0, displayed reduced exploration with a lower number of arm entries but no change in the SA (F). No alteration was detected in the rotarod test with
similar progress during the learning and the test phases (G). (Values represent means + S.E.M. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001).
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Figure 4. Pharmacological intervention to suppress the consequences of CBS overexpression in yeast (A–C) and mouse (D). Development of a yeast screening assay
based on Cys4-overexpressing cells and identification of DSF as able to suppress methionine auxotrophy induced by Cys4 overexpression. The sensitivity of the strain
to the absence of methionine in the medium was evidenced by serial dilutions of a yeast strain expressing different levels of Cys4 (A). For the drug screening, the yeast
strain overexpressing Cys4 from both p424 & p426 2 μ multicopy plasmids was spread on a square Petri plate containing solid agar-based methionine-free medium.
DMSO was used as a negative control and added to the upper right filter and methionine, the positive control, was loaded on the bottom left filter (B). At the remaining
positions, individual compounds from the chemical libraries were added and plates were incubated for 3 days at 33◦C. Three types of growth profiles can be observed
around the filters where the compounds were loaded. Either the compounds have no effect, which results in the same basal growth (indeed, the overexpression of Cys4
does not lead to a completemethionine auxotrophy as evidenced in C), or it is toxic,which results in a total absence of growth (visualized as a dark halo corresponding to
the colour of the solid media). The last possibility corresponds to active drugs that suppress the methionine auxotrophy, thereby leading to a halo of enhanced growth
around the filter. Of note, a single compound can display various effects (which is the case for DSF, see below), it can be toxic at high concentration (immediately
around the filter), thereby leading to a halo of non-growing cells at the immediate vicinity of the filter and then become active at sub-toxic concentrations that leads to
a crown of cells growing at a faster rate (leading to the formation of bigger colonies) and then become inactive at sub-active concentrations (at a bigger distance from
the filter). The dose-dependent effect of DSF on Cys4-overexpressing cells is shown, and its molecular structure is depicted (C). To test DSF in mice, treatment was done
on Tg(CBS) cohort starting at D1 and ending at D10 (D). Each group received a daily dose of 10 mg/kg/day of DSF for 10 days followed by an open field paradigm (D10)
with the object recognition test performed on D11 (with 1 h of retention time). The graph at the bottom showed the percentage of time spent on the novel versus the
familiar object during the tests. The vehicule-treated wt mice were able to discriminate both objects as the DSF-treated Tg(CBS) animals. On the contrary, non-treated
transgenic animals were not able to do so and the DSF-treated wt animals were impaired in the test confirming that the drug affects the consequences of CBS activity
in vivo (values represent means + S.E.M. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001).
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that the phenotypical consequences of the overexpression of
CBS could be targeted by drugs to restore some of the cognitive
performance altered in DS models. They also emphasize that
the inhibition of CBS, direct or indirect, should be mild and only
partial as a strong inhibition may be detrimental as illustrated
by the cognitive dysfunction observed in homocystinuria.
Epistatic interaction between Dyrk1a and the Abcg1-Cbs
region drives recognition memory in DS mouse models
Dyrk1a is a major driver gene of DS cognitive defects (55) and
a decrease in Cbs dosage is known to change the expression of
Dyrk1a in the brain and other organs (56–58). Thus in order to
test the functional interaction of Cbs and Dyrk1a overdosage,
we combined the Dp1Yah with the Tg(Dyrk1a) mouse model,
with Dyrk1a mRNA expression ratio around 1.5 compared
with control littermate (32) and the overexpression of the
protein and its kinase activity (33). Tg(Dyrk1a) mice present
increased spontaneous activity compared with wt in the open
field test. This hyperactivity was also observed in the double
transgenic Dp1Yah/Tg(Dyrk1a) while it was absent from Dp1Yah
animals [Fig. 5A, Student t-test wt versus Dp1Yah P = 0.460, wt
versus Tg(Dyrk1a) P = 0.002 and wt versus Dp1Yah/Tg(Dyrk1a)
P = 0.006, Tg(Dyrk1a) versus Dp1Yah/Tg(Dyrk1a) P = 0.200]. Hyper-
activity was confirmed in the Y-maze, with both Tg(Dyrk1a)
and Dp1Yah/Tg(Dyrk1a) performing more arms visits than
the controls and Dp1Yah mice [Fig. 5B, Student t-test wt
versus Dp1Yah P = 0.800, wt versus Tg(Dyrk1a) P = 0.005 and
wt versus Dp1Yah/Tg(Dyrk1a) P = 0.005, Tg(Dyrk1a) versus
Dp1Yah/Tg(Dyrk1a) P = 0.881]. The working memory defect
observed in the Y-maze for Tg(Dyrk1a) mice was not rescued
in Dp1Yah/Tg(Dyrk1a) double transgenic mice [Fig. 5B, one-
way ANOVA F(3, 48) = 4.14 P = 0.011, post hoc Tukey method
wt versus Tg(Dyrk1a) P = 0.042, wt versus Dp1Yah/Tg(Dyrk1a)
P = 0.019 and Tg(Dyrk1a) versus Dp1Yah/Tg(Dyrk1a) P = 0.203].
Then, we tested the NOR memory after 1 h of retention (Fig. 5C).
As expected, the two single mutants were impaired [two ways
ANOVA, variables ‘genotype’ and ‘objects’: F(3, 70) = 7.09 with
P < 0.001, post hoc Tukey test: Dp1Yah ‘fam versus new’ q = 1.333
and P = 0.349, Tg(Dyr1a) q = 1.732 and P = 0.225; recognition index,
one sample t-testmean versus 50%: Dp1Yah P = 0.253, Tg(Dyrk1a)
P = 497] but the double transgenic mice Dp1Yah/Tg(Dyrk1a) were
able, similarly to wt littermates, to discriminate the familiar
versus novel objects [two ways ANOVA, variables ‘genotype’ and
‘objects’: F(3, 70) = 7.09 with P < 0.001, post hoc Tukey test: wt
‘fam versus new’ q = 4.543 and P = 0.002, Dp1Yah/Tg(Dyr1a)
q = 5.289 and P < 0.001; recognition index, one sample t-test:
wt P = 0.048, Dp1Yah/Tg(Dyrk1a) P = 0.011], suggesting that
the effects of Dyrk1a overexpression are compensated by three
copies of the Abcg1-Cbs region.
Lastly, we checked the learning and spatial memories using
the Morris water maze task, followed by a probe test 24 h after
the learning period (Fig. 5D). Even if all the groups increased
their performance to reach the platform during the learning
phase, after 6 days of training (J1–J6), wt and Dp1Yah mice
found the platform with lower latency than the Tg(Dyrk1a) and
Dp1Yah/Tg(Dyrk1a) [two ways ANOVA variable genotype, F(3,
280) = 14.80 P < 0.001, post hoc Tukey test: wt versus Tg(Dyrk1a)
q = 6.160 with P < 0.001, wt versus Dp1Yah/Tg(Dyrk1a) q = 4.752
with P = 0.004, Dp1Yah versus Tg(Dyrk1a) q = 8.103 with P < 0.001,
Dp1Yah versus Dp1Yah/Tg(Dyrk1a) q = 6.641 with P < 0.001].
During the probe test, 24 h after the learning phase, controls and
Dp1Yah animals were most of their time, searching in the plat-
form quadrant (T), whereas Tg(Dyrk1a) and double transgenic
mice searched randomly across the entire space [one sample t-
test versus 50% mean: wt P = 0.02, Dp1Yah P = 0.05, Tg(Dyrk1a)
P = 0.99 and Dp1Yah/Tg(Dyrk1a) P = 0.57]. Hence, overexpressing
Cbs and Dyrk1a does not rescue the Dyrk1a dosage-dependent
working and spatialmemory deficits observed in theY-maze and
the Morris water maze, respectively, neither the hyperactivity
observed in the open field, but rescued the object recognition
impairment.
Proteomics unravels complex intermingled proteomic
changes influenced by DYRK1A overexpression and by
Dp1Yah trisomic genes
In order to unravel the impact of CBS and DYRK1A on cellular
mechanism within the hippocampus that could lead to the
memory phenotype observed in the NOR test, we profiled the
proteome in the hippocampi isolated from Dp1Yah, Tg(Dyrk1a)
and double [Dp1Yah, Tg(Dyrk1a)] animals and compared them
with the wt control littermates. We collected the samples after
the behavioural evaluation and performed a TMT labelling
(Thermo Scientific, Illkirch) followed by LC-MS/MS orbitrap
analysis. We were able to detect 1655 proteins of which 546
were detected in all the three genotypes with a variability below
40% (Supplementary Material, Table S4) and among which 338
proteins were expressed at the same level as control ones.
A total of 208 proteins were found differentially expressed
with levels of expression above 1.2 (206) or below 0.8 (2) in
Dp1Yah, Tg(Dyrk1a) and double mutant mice (Fig. 6A). Nine
proteins were up-regulated in all three genotypes: the RIKEN
cDNA 6430548 M08 gene product (6430548M08RIK), actin-
related protein 2/3 complex, subunit 1A (ARPC1A), bridging
Integrator 1 (BIN1), the family with sequence similarity 213,
member A (Fam213a), glyoxalase 1 (GLO1), importin 5 (LPO5),
NADH dehydrogenase (ubiquinone) Fe-S protein 1 (NDUFS1),
prostaglandin reductase 2 (PTGR2) and SNAP25. ToppCluster
analysis of the protein content unraveled a general common
network with interacting proteins modified by the three genetic
conditions (Fig. 6B–C). Functional analysis using gene ontology
highlighted several cellular components affected in the three
genotypes including synaptic particles, neuron projection,
presynapse/synapse, axon, myelin sheath and different types
of vesicles (Supplementary Material, Table S5). Cell/neuron
projection development, morphogenesis and differentiation,
as well as secretion, synaptic and anterograde trans-synaptic
signalling were affected in Dp1Yah while aldehyde catabolic
processes and regulation of anatomical structure sizeweremod-
ified in Tg(Dyrk1a). Interestingly, all these biological processes
were not disturbed in double transgenic animals. Likewise,
molecular functions controlling ubiquitin protein ligase, calcium
ion binding and dicarboxylic acid transmembrane transporter
activity deregulated in Dp1Yah or cytoskeletal protein and
myosin binding perturbed in Tg(Dyrk1a) were restored [Dp1Yah,
Tg(Dyrk1a)]. On the contrary, oxidoreductase activity was newly
modified in the double transgenic hippocampi.
We selected three proteins with different proteomic profiles
in hippocampi and studied their expression in another brain
region, the cerebral cortex, usingwestern blot analysis: the SNCA
and the FUS proteins, which are associated with neurodegen-
erative disease (59–62) and the SNAP25, a component of the
SNARE complex involved in calcium-triggered exocytosis (63–
65). As shown in Figure 5D, levels of SNCA were similar to wt
level. We did observe the increased amount of this protein in
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Figure 5. CBS and DYRK1A overdosages interact to control behaviour and cognition. Behavioural and cognitive analysis of transgenic animals overexpressing Cbs and
Dyrk1a (14 wt, 15 Tg(Dyrk1a), 13 Dp1Yah and 13 (Dp1Yah,Tg(Dyrk1a)) mutant mice in the open field (A), the Y-maze (B), the object recognition (C) and the Morris water
maze (D). Increased activity in the open field (A) and in the number of arm entries in the Y-maze (B) were found in the Tg(Dyrk1a) and (Dp1Yah,Tg(Dyrk1a)) animals
with also reduced SA in the Y-maze (B). Both the Dp1Yah and (Dp1Yah,Tg(Dyrk1a)) mutant mice were impaired in object recognition (C) but the double mutant animals
showed restored object discrimination similar to wt littermates. The Tg(Dyrk1a) and (Dp1Yah,Tg(Dyrk1a)) animals displayed delayed learning in the Morris water maze
with no memory of the platform location in the probe test compared with Dp1Yah and wt littermates (D). (Values represent means + S.E.M. ∗P < 0.05, ∗∗P < 0.01,
∗∗∗P < 0.001).
the [Dp1Yah, Tg(Dyrk1a)] animals contrary to what was observed
in the proteome analysis. The presynaptic SNAP25 protein was
significantly up-regulated in cortical regions of the [Dp1Yah,
Tg(Dyrk1a)] animals and to a lesser extent in the Dp1Yah and
Tg(Dyrk1a) ones {Student t-test wt versus Tg(Dyrk1a) P = 0.233,wt
versus Dp1Yah P = 0,06, wt versus [D1Yah, Tg(Dyrk1a)] P = 0.02}.
Hence, in the proteomic approach,we also observed the increase
previously detected in the hippocampus of those three trans-
genic lines. The RNA-binding protein FUS was found overex-
pressed in the Dp1Yah brains and to a lesser extent in the
[Dp1Yah, Tg(Dyrk1a)] ones, similarly to what was observed in
the proteomic analysis {Student t-test Dp1Yah compared to wt
P = 0.02 and [Dp1Yah, Tg(Dyrk1a)] compared with wt P = 0.09}.
Discussion
In this report, we demonstrated that the genetic overdosage of
Cbs is necessary and sufficient to induce defective NOR in three
different types of DS models. CBS overdosage is certainly the
main driver of the learning and memory phenotypes detected
previously in DS models for the Mmu17 region (21,22) but we
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Figure 6. Pattern of protein expression is disrupted upon changes in DYRK1A and CBS dosage. (A) Analyzing the 1655 proteins detected in the Orbitrap ELITE experiment,
we extracted from Proteome Discoverer 1.4© a list of 208 proteins dysregulated in our different sample conditions. The association between proteins, pathways and
genotypes is summarized in two Venn diagrams (B–C).We deduced that the trisomic alleles inducedmost of the perturbations; moreover, the combination of increased
DYRK1A and trisomic condition led to new dysregulations. (D) Western blot validation of three protein candidates SNCA, SNAP25 and FUS. SNAP25 expression is
increased in samples overexpressing DYRK1A.More interestingly, FUS was found significantly up-regulated in Dp1Yah, plots represent every sample values normalized
with β-actin level. (Values represent means + S.E.M. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001).
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cannot rule out the possibility that one or more another gene(s)
contribute, with Cbs, to the phenotype. Previous analysis of CBS
overdosage with the same transgenic line Tg(CBS) on the FVB/N
genetic background showed no change in fear-learning task
and locomotor activity but increased LTP-dependent synaptic
plasticity (66); a phenomenon also detected in vitro and in vivo in
other DS models in which Cbs is trisomic in the C57BL/6J genetic
background (21,22). Nevertheless, no positive effect on cognition
is associatedwith increase in CBS dosage as previously proposed
by Régnier et al. (66). Instead, the overdosage of CBS always
impairs the hippocampal-dependent NOR test suggesting that
increased synaptic plasticity found in Cbs trisomic models
may alter synaptic functions. Increased synaptic plasticity
could occur via increased H2S as it has been shown that H2S
facilitates LTP by stimulating the post-synaptic NMDA receptors
(67,68). Moreover, a role of H2S has been foreseen in calcium
homeostasis regulation that is also crucial for neuronal synaptic
plasticity (69).
DSF was isolated from a drug screening performed in yeast
cells overexpressing CBS homolog Cys4p and looking for drugs
counteracting its effect on methionine auxotrophy. Although
DSF has been first identified as an inhibitor of mitochondrial
ALDH (70), it is a relatively nontoxic substance, which has been
on themarket formore than 40 years to support the treatment of
chronic alcoholism by producing an acute sensitivity to ethanol,
leading to an accumulation of acetaldehyde in blood when
alcohol is ingested. As acetaldehyde is responsible for many of
the unpleasant effects that follow ingestion of large quantities
of alcohol (‘hangover’), DSF treatment discourages the patients
to sustain a regular alcohol consumption by exacerbating and
accelerating its unpleasant side effects. DSF is known to have a
sedative effect both in mouse and patients. It is thus possible
that this side effect reduces the ability of treated wt mice to
perform the object recognition test as efficiently as non-treated
mice. Further studies are necessary to better understand the
mode of action and identify the targets of DSF affected in this
behavioural test. Our ongoing studies about the mechanism of
action of DSF suggest that this molecule may not directly inhibit
CBS enzymatic activity but probably rather acts on the cellular
consequences of CBS overexpression. The assay used for the
screening allows, in principle, the isolation of drugs acting both
directly or not on CBS/Cys4. This latter point is of importance
given that CBS may not be a druggable target enzyme. And
indeed, at present, we do not know if DSF is acting directly
or indirectly on CBS but we must assume that the function
altered by CBS overdosage, whatever it is, is conserved and
similarly sensitive to DSF treatment in both yeast andmouse. Of
note, upon absorption, DSF is rapidly reduced to diethyldithio-
carbamate (DDC), which then reacts with thiol groups. Both
DSF and DDC are potent copper chelators, thereby possibly
affecting the activity of copper-dependent enzymes such as
monooxygenases, the Cu–Zn superoxide dismutase, amine
oxidase, ADNmethyltransferases, and cytochrome oxidase. As a
result, DSF has been shown to affect various cellular processes
such as cocaine metabolism and catecholamine synthesis and
proteasome inhibition and is thus under study for multiple clin-
ical applications that include struggle against alcohol addiction,
cancer chemotherapy, treatment of copper-related disorders
and anti-viral treatment for hepatitis C and human immunod-
eficiency virus (71). Here, we describe a new possible clinical
application of DSF in DS cognition through its effect on the con-
sequences of CBS overexpression. CBS clearly represents a new
relevant therapeutic target for improving DS cognition and DSF,
as such, opens new therapeutic avenues in patients with DS.
We also demonstrated that CBS genetically interacts
with Dyrk1a, a well-known therapeutic target for DS. Mutual
relationships between DYRK1A and CBS have previously been
reported, with decreased DYRK1A protein observed in the liver
(Hamelet et al., 2009) and increased expression observed in the
brain of Cbs+/− mice (Planque et al., 2013), while overexpression
(or under-expression) of DYRK1A induce accumulation (or
reduction) of CBS expression in the liver (72). In order to
explore the genetic interactions between DYRK1A and CBS, we
overexpressed Dyrk1a in the Dp1Yah context by combining the
Tg(Dyrk1a) and the Dp1Yah mice. Surprisingly, this experiment
restored memory that is lacking in the Dp1Yah mouse model in
the object recognition task, but neither normalized the increased
locomotor activity in the open field or the Y-maze nor the
working and spatial memory deficits. Thus, the compensation is
restricted to a specific cognitive function, recognition memory,
which is defective in both TgDyrk1a and Dp1Yah models.
Why this dosage effect is restricted to recognition memory
remains speculative. We may hypothesize that Cbs and Dyrk1a
overdosage only interact in specific regions of the adult
brain involved in object discrimination explaining why the
increased locomotor activity and the working and visuo-spatial
phenotypes induced in Tg(Dyrk1a) animals are not affected.
Alternatively, the object recognition deficit is likely to result
from an impact of DYRK1A on adult brain function while the
other phenotypes are the result of an impact during earlier
stages of brain development.On the one hand, object recognition
has been shown to require undamaged hippocampal perforant
path connecting ento/perirhinal cortex with the dentate gyrus
for long retention intervals (>15 min) in the rat (73–78). On the
other hand, synaptic exchanges between the median prefrontal
cortex and the hippocampus seem to be sufficient to support
the processing of short-term memory such as working memory
observed in the Y-maze (79,80) and hyperactivity is associated
with the prefrontal cortex, basal ganglia and cerebellum
(81–84). Moreover, long-term recognition memory has been
shown to appear in the rat at weaning (post-natal day 21 in the
mouse) (85), a period corresponding to the end of neurogenesis
and synaptogenesis in the dentate gyrus of the hippocampus,
and reflecting the general observation of ‘infantile amnesia’
observed on long-term memory tasks but not on short-term
memory ability (86).
Our proposal goes farther than the demonstration by Zhang
et al. (23) that the Hsa21 homologous region on the Mmu17 is a
key determinant of cognitive deficits in DS mouse models. We
showed here that CBS is a key gene for DS-related phenotypes in
mice with the other homologous interval Cbr3-Fam3b located on
Mmu16, encompassing Dyrk1a. We should also consider that in
people with DS, both genes are trisomic and thus the recognition
memory deficit observed in DS persons and in the complete T21
mouse model (87) certainly depends not only on the interplay
between DYRK1A and CBS but also on interaction with other
Hsa21 genes that may affect different pathways or different
parts of the brain.
The molecular mechanisms involved in Cbs-Dyrk1a genetic
interaction have been investigated through a quantitative pro-
teomic approach. Although limited due to the complexity of the
hippocampus, the results highlight protein network interactions
between the two trisomic regions. A total of 208 proteins were
found deregulated, corresponding to 148GO categories and path-
ways, with 72 specific to Dp1Yah (out of 121) and 9 to Dyrk1a
transgenic model (out of 32, Supplementary Material, Table S5)
and 5 shared between Dp1Yah and Tg(Dyrk1a). More interest-
ingly, GO terms such as cortical cytoskeleton or cytoskeletal
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protein binding were respectively affected in Dp1Yah and in the
Tg(Dyrk1a) but were restored in the double transgenic animals,
uncovering somehow the nature of the pathways controlled by
the epistatic interaction between CBS and DYRK1A overdosage.
DYRK1A is mainly found associated with the actin cytoskele-
ton modulation (88). CBS is the major enzyme involved in H2S
production in the central nervous system (67). Interestingly, an
increase of H2S activates RAC1 leading to the rearrangement
of the actin cytoskeleton during endothelial cell migration (89).
Thus, a simple hypothesis would be that the overdosage of CBS
may lead to increased H2S production and further activation
of RAC1 with effect on actin cytoskeleton rearrangement, a
key mechanism involved in synaptic transmission. Remarkably,
DYRK1A interacts with p120-catenin-Kaiso and can then modu-
late Rac1 (90). Thus, one working hypothesis is based on CBS and
DYRK1A pathways connected through RAC1.
DYRK1A is themain driver of defects in DSmousemodels for
the homologous region to Hsa21 located on Mmu16 (55). Based
on a previous study performed in DS models for the Mmu16
homologous region (91), DYRK1A has been selected as a drug
target. As reported previously, treatment with epigallocatechin-
3-gallate, an inhibitor of DYRK1A kinase activity, can restore
some cognitive aspects found altered in people with DS but the
gain was limited (16,17). Nevertheless, our results, by adding CBS
to the limited number of DS therapeutic targets, may improve
the efficiency of DS treatment, in particular by combining mul-
tiple therapies to improve the life of DS patients. Finally, an
important point to emphasize is that, for DYRK1A as well as
for CBS, both loss-of-function mutations and overdosage lead
to intellectual deficiencies. This is important to keep in mind
when considering a pharmacological intervention that aims at
inhibiting one or the other, or both, of these enzymes. Therefore,
drug treatment that leads to only amild inhibition of CBS and/or
DYRK1A should be favoured.
Supplementary Material
Supplementary Material is available at HMG online.
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